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_padmaja2001@yaAbstract Rapid and sensitive reversed phase high performance liquid chromatography (RP-HPLC) and
ultra performance liquid chromatography (RP-UPLC) method with UV detection has been developed
and validated for quantiﬁcation of parathyroid hormone (PTH) in presence of meta-cresol as a stabilizer
in a pharmaceutical formulation. Chromatography was performed with mobile phase containing 0.1%
Triﬂuoroacetic acid (TFA) in MilliQ water and 0.1% TFA in acetonitrile with gradient program and ﬂow
rate at 0.3 mL/min for HPLC and 0.4 mL/min for UPLC. Quantiﬁcation was accomplished with internal
reference standard (qualiﬁed against innovator product and National Institute for Biological Standards
and Control (NIBSC) standard). The methods were validated for linearity (correlation coefﬁcient¼0.99),
range, accuracy, precision and robustness. Robustness was conﬁrmed by considering three factors; mobile
phase composition, column temperature and ﬂow rate/age of mobile phase.
Intermediate precision was conﬁrmed on different equipments, different columns and on different days.
The relative standard deviation (RSD) (o2% for RP-HPLC and o1% for UPLC, n¼30) indicated a
good precision. Retention time was found about 17 min and 2 min by HPLC and UPLC methods,
respectively. Both methods are simple, highly sensitive, precise and accurate and have the potential of
being useful for routine quality control.
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1. Introduction
Parathyroid hormone (PTH) is secreted by the parathyroid
glands as a polypeptide containing 84 amino acids. It acts to
increase the concentration of calcium (Ca2þ) in the blood.
A smaller fragment of the full length hormone PTH (1-34)
crystallizes as a slightly bent, long helical dimer. Analysis reveals
that the extended helical conformation of PTH (1-34) is the likely
bioactive conformation [1]. Human parathyroid hormone, a
peptide of 84 amino acid residues [2] secreted from parathyroid
gland, is the principle homeostatic regulator of the level of blood
Quantiﬁcation of parathyroid hormones (1-34) with m-cresol 137calcium through its actions on kidney and bone [3]. Teriparatide
(recombinant DNA origin) injection [recombinant human PTH
(1-34)] is a bone-forming agent for the treatment of osteoporosis.
In the Fracture Prevention Trial (FPT), daily self-injections of
teriparatide (20 and 40 mg) reduced the risk of new vertebral and
non-vertebral fractures by 65% and 53%, respectively, in
postmenopausal women with advanced osteoporosis [4]. Once-
daily injection of PTH induced pronounced increase in biochem-
ical markers of bone turnover [5–10].
Immunoassay is a common technique for measurement of
PTH in plasma. The measurement of PTH and its metabolites
has been problematic due to the diversity of the circulating
PTH metabolites, differences in the pharmacokinetic proﬁles
of PTH and its metabolites and signiﬁcant differences in
speciﬁcity and sensitivity of PTH radioimmunoassay [11–13].
Methionine oxidation in PTH was studied by Nabuchi et al.
by using RP-HPLC [14]. WHO International collaborative
study of the proposed 1st international standard for recombi-
nant human PTH (1-84) was done by RP-HPLC method in
different laboratories [15]. Liquid chromatographic studies on
separation of ten PTH amino acids were carried out using
normal phase untreated silica gel plate, C-18 RP precoated
plates and RP-HPLC by Bhushan and Agarwal [16]. Separa-
tion, characterization and biological activity of PTH oxidized
at methionine 8 and methionine 18 were studied by Frelinger
and Zulls [17]. PTH was oxidized with hydrogen peroxide and
the biological activity of oxidation products was studied by
Nabuchi et al. [18].
The recombinant human (rHu) PTH (1-34) formulation
contains meta-cresol as antimicrobial preservative, which may
interfere with OD280 UV detector of HPLC as well as with
colorimetric assays. An RP-HPLC/UPLC method, which can
speciﬁcally measure the protein component of Active Pharma-
ceutical Ingredient (API) with separation of meta-cresol from
protein peaks, will be suitable for quantitation of the active
substance in presence of meta-cresol. The objective of the
study was to develop methods, using RP-HPLC and UPLC
techniques to enable quantiﬁcation of PTH in medicinal
formulations containing meta-cresol.
This paper reports rapid and sensitive methods with UV
detection, which are useful for routine quality control of PTH
in pharmaceutical formulations. Both the methods are vali-
dated by parameters such as linearity, accuracy, precision and
robustness. To the best of our knowledge, no UPLC method
has been reported.2. Experimental
2.1. Materials, reagents and chemicals
HPLC grade acetonitrile and methanol were purchased from
Merck, tri-ﬂuoro-acetic acid was purchased from Sigma
Aldrich. Ultra pure water was obtained using Milli-Qs UF-
Plus (Millipore) system, meta-cresol was obtained from J.T.
Baker/Hedinger. Reference medicinal product (Innovator
drug product) having a concentration of 250 mg/mL and
PTH internal reference standard (IRS) were used for prepara-
tion of standards in all experiments. Formulated PTH was
used as samples. All other chemicals such as mannitol, sodium
acetate and glacial acetic were of the highest purity available.2.2. Preparation of standard, mobile phase and dilution buffer
Diluted PTH standard was prepared using 400 mg/mL of PTH
IRS in mobile phase A. Mobile phase ‘A’ consisted of 0.1%
(v/v) TFA in MilliQ water and mobile phase ‘B’ consisted
of 0.1% (v/v) TFA in acetonitrile. Dilution buffer containing
3 mg/mL meta-cresol, 45.4 mg/mL mannitol, 0.1 mg/mL
sodium acetate and 0.41 mg/mL glacial acetic acid in ‘‘MilliQ
water’’ was prepared and used so as to have a matrix similar to
PTH formulation. Oxidized form of PTH was prepared by
adding 4.0 mL of diluted 0.25% H2O2 to 62.6 mL of PTH drug
substance (0.4 mg/mL), mixed well, incubated for 40 min at
room temperature and then quenched with 37.4 mL of 50 mg/mL
methionine. All dilutions were made using calibrated digital
micro-pipettes.
2.3. Chromatographic condition
Agilent LC system (1100 and 1200 series) equipped with an
injection valve (quaternary), 210 UV detector and Chemsta-
tion software was used for HPLC method. A reversed-phase
C18 column (2.1 mm ID 100 mm L, porosity 300 A˚, particle
size 3 mm) with guard column (reversed-phase C18 column of
2.1 mm ID 12.5 mm L, porosity 300 A˚, particle size 5 mm)
was used for separation. To get the optimum results, mobile
phase with a ﬂow rate of 0.3 mL/min was used and column
temperature was maintained at 60 1C. The gradient program
for mobile phase was optimized using a timed gradient
program T (min)/mobile phase A (%): 0/80, 6/80, 26.1/45,
28/0, 31/0, 31.5/80, and 40/80.
Waters LC system (ACQUITY) equipped with an injection
valve (binary), 215UV detector and Empower software was
used for RP-UPLC method. Reversed-phase C8 column
(2.1 mm ID 12.5 mm L, porosity 300 A˚, particle size 5 mm)
was used for separation. To get the optimum results, mobile
phase ﬂow rate was kept constant at 0.4 mL/min, column
temperature at 60 1C. The gradient program for mobile phase
was optimized using a timed gradient program T (min)/mobile
phase A (%): 0/80, 1.2/80, 4.8/0, 5/80, and 6/80.
2.4. Validation of chromatographic methods
Method validation is the process used to conﬁrm that the
analytical procedure employed for a speciﬁc test is suitable for
its intended use [19,20]. The optimized chromatographic
methods were validated according to the procedures described
in International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH) guidelines Q2 (R1) in terms of accuracy, precision,
speciﬁcity, linearity and range, robustness, etc. [21].3. Results and discussion
3.1. RP-HPLC method
3.1.1. Method development
Initially, the gradient HPLC conditions were optimized for
determination of PTH in presence of meta-cresol. The chro-
matographic separation was achieved by applying chromato-
graphic conditions described in Section 2.3.
S.S. Rane et al.138The applied chromatographic conditions permitted a good
separation of meta-cresol and PTH at different concentrations
of PTH. No interference of other excipients or oxidized
impurities was observed (Figs. 1 and 2).
The capacity factor (k0) of the ﬁrst peak (meta-cresol) and
second peak (PTH) was 1.60 and 11.5, respectively; while the
resolution factor was 6.88. The asymmetry of the peak for
meta-cresol and PTH was found to be 0.26 and 1.06,
respectively; while the tailing factor parameter for meta-cresol
and PTH was found to be 3.62 and 1.36, respectively.
Based on the studied parameters, it was concluded that the
developed method is optimum. PTH, oxidized impurities and
meta-cresol peaks were well resolved and the tailing factor was
within limits.
3.1.2. Method validation
3.1.2.1. Speciﬁcity. To evaluate possible interfering peaks,
PTH standard (250 mg/mL) in mobile phase (as positive
control), API, drug product (to verify the separation of
interested protein from other components) and oxidized API
(to conﬁrm the separation of oxidized forms of protein from
the interested protein) were injected into HPLC and no
interference was observed (Fig. 2).
3.1.2.2. Linearity and range. PTH IRS was used for prepara-
tion of different concentrations ranging from 100 to 312 mg/mL.
Linearity curve was plotted for of peak area responses versus
concentration of PTH, which is shown in Fig. 3. The cor-
relation coefﬁcient, slope, Y-intercept, regression equation of
the calibration curve were determined and the results are
shown in Table 1. The percent RSD was found to be less than
2.0% while the percent recovery was found to be in the range
of 97–103%.
3.1.2.3. Accuracy. Accuracy was studied by spiking PTH in
the range of 200, 250 and 312 mg/mL in the mobile phase. TheFigure 1 Overlapped HPLC chromatograms of (A) mobile phase (as
phase, formulation buffer and PTH drug product were injected into HP
acid (TFA) in MilliQ water and 0.1% TFA in acetonitrite. (B) Fo
mannitol, 0.3 mg/mL sodium acetate and 0.41 mg/mL glacial acetic acid
of PTH and mg/mL ‘meta-cresol’.percent recovery was found to be in the range of 95–105%.
The percent RSD was found to be less than 2.0%.
3.1.2.4. Precision. Precision was evaluated on intra-day
(Repeatability) and inter-day (intermediate precision) varia-
tion, and different columns. Intra-day study was determined
by performing six independent preparation of the standard
preparation of drug substance (250 mg/mL) and drug product
(250 mg/mL). The percent RSD of main peak area was found
to be less than 0.5%. Inter-day precision was determined by
performing ﬁve different conditions along with the ﬁve
replicates for each condition, which is equivalent to n¼25
(5 5). The percent RSD of the main peak area was found to
be less than 0.5% within each set and less than 2.0% between
different sets. The percent recovery was found to be between
95.0% and 105.0% and the maximum variation between sets
was found to be less than 5.0%.
3.1.2.5. Robustness. The robustness is a measure of its
capacity to remain unaffected by small, but deliberate varia-
tions in method parameters and provides an indication of its
robustness during normal usage. Robustness was tested using
three variables: ﬂow rate, column temperature and mobile
phase composition.
3.1.2.6. Flow rate. Experiments were conducted using system
suitability samples with ﬂow rate variation of þ10% from the
set ﬂow rate (0.3 mL/min). The percent RSD was found to be
less than 2%, with no variation and þ0.1 min difference in
retention time but during lower side of ﬂow rate, we found
higher percentage of recovery (i.e. about 111%) whereas
during higher side of ﬂow rate, we found lower percentage
of recovery (i.e. about 93%). Based on recovery, it was
concluded that ﬂow rate is critical parameter.
3.1.2.7. Column temperature effect. Experiments were con-
ducted using system suitability samples with columnblank), (B) formulation buffer and (C) PTH drug product. Mobile
LC separately. (A) Mobile phase—containing 0.1% triﬂuoroacetic
rmulation buffer (without meta-cresol)—containing 45.5 mg/mL
in MilliQ water. (C) PTH drug product—containing 0.250 mg/mL
Figure 2 HPLC chromatogram of PTH oxidized form. Oxidized form of PTH was prepared by adding 4.0 mL of diluted 0.25% H2O2 to
62.6 mL of PTH drug substance (0.4 mg/mL), mixed well, incubated for 40 min at room temperature and then quenched with 37.4 mL of
50 mg/mL methionine.
Figure 3 Linearity curve (HPLC) for PTH. PTH drug substance
(400 mg/mL) was diluted with mobile phase A for preparation of
different concentrations ranging from 100 to 312 mg/mL and
injected separately.
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(60 1C). The percent RSD was found to be less than 2%, with
no variation and þ0.1 min difference in retention time. The
percent recovery was found to be within acceptable limits (95–
105%) and hence column temperature was not considered to
be critical parameter.
3.1.2.8. Mobile phase composition. Experiments were con-
ducted using system suitability samples with mobile phase
composition variation of 720% from the set percentage of
TFA (0.1%). Results for triplicate injections (% variation)
between unaltered/initial condition and altered condition for
PTH sample were found to vary less than 2.0% without
variation in retention time and hence mobile phase composi-
tion was not considered to be critical parameter.3.2. UPLC method
3.2.1. Method development
The basic chromatographic conditions like stationary phase,
solvents and UV detector, employed in HPLC were taken into
account while developing new UPLC method. The stationary
phase C8 was chosen in order to have similar polarity as that
used in HPLC. The injection volume was scaled down byabout 5 fold as used in HPLC. To get the optimum results,
mobile phase ﬂow rate was kept constant at 0.4 mL/min and
column temperature was maintained at 60 1C. The chromato-
graphic separation was achieved as described in Section 2.3.
The applied chromatographic conditions permitted a good
separation of meta-cresol and PTH at different concentrations
of PTH. No interference of other excipients or other oxidized
impurities was observed during the analysis (Figs. 4–6).
The capacity factor (k0) of the main peak (PTH) was 11.60;
while tailing factor was found to be 1.24. It can be thus
concluded that PTH, oxidized forms of PTH and meta-cresol
peaks were well resolved in the developed method and the
tailing factor was within limits.
3.2.2. Method validation
3.2.2.1. Speciﬁcity. To evaluate possible interfering peaks,
PTH standard (150 mg/mL) in mobile phase (as positive
control), API, drug product (to verify the separation of
interested protein from other components), oxidized API
and oxidized drug product (to conﬁrm the separation of
oxidized forms of protein from the interested protein) were
injected into UPLC and no interference was observed (Fig. 6).
3.2.2.2. Linearity and range. PTH RS and samples were
chromatographed using the set chromatographic conditions.
Linearity curves were plotted for 50–300 mg/mL of PTH
(Fig. 7). The linearity of peak area responses versus concen-
tration for PTH was studied and correlation coefﬁcient, slopes
and Y-intercepts and regression equation were determined and
the results are shown in Table 1. The correlation coefﬁcient
was found to be 0.999. The percent RSD was found to be less
than 2.0% while the percent recovery was found to be in the
range of 98–105%.
3.2.2.3. Accuracy. Accuracy was studied using six different
solutions, containing 50, 100, 150, 200, 250 and 300 mg/mL of
PTH. Three replicates of each solution were spiked in the
mobile phase. (n¼6 3¼18). The percent recovery was found
to be in the range of 95–105%. The percent RSD was found to
be less than 2.0%.
3.2.2.4. Precision. Precision was evaluated on intra-day
(Repeatability) and inter-day (intermediate precision) e.g.
variation between different equipment, and same makes but
Table 1 Results of regression equation/correlation coefﬁcient and both methods comparative data.
Statistical parameter RP-HPLC UPLC
Linearity and range (concentration, mg/mL) 100–300 50–300
Regression equation y¼82.16847.221 y¼12203.822694815.0889
Correlation coefﬁcient (R2) 0.999 0.999
Total analysis time (min) 40 6
Retention time (min)
For meta-cresol 3.5 0.3
For PTH 16.4 1.9
Flow rate (mL/min) 0.3 0.4
Column C18 C8
(2.1 mm 100 mm) (2.1 mm 12.5 mm)
3 mm, 300 A˚ 5 mm, 300 A˚
Column condition C18, 210 UV C8, 215 UV
Method Gradient Gradient
Sample size 20 mL 4 mL
Speciﬁcity No interference No interference
Accuracy Recovery between 95% and 105% Recovery between 95% and 105%
Precision RSD o3.0% RSD o1.0%
Robustness Yes Yes
Figure 4 Overlapped UPLC chromatograms of (A) mobile phase, (B) formulation buffer and (C) PTH drug substance (without meta-cresol).
Mobile phase, formulation buffer and PTH were injected into HPLC separately. (A) Mobile phase—containing 0.1% triﬂuoroacetic acid (TFA) in
MilliQ water and 0.1% TFA in acetonitrite. (B) Formulation buffer (without meta-cresol)—containing 45.5 mg/mL mannitol, 0.1 mg/mL sodium
acetate and 0.41 mg/mL glacial acetic acid in MilliQ water. (C) PTH drug substance—containing 0.250 mg/mL of PTH in MilliQ water.
S.S. Rane et al.140different lots of UPLC columns were studied. Intra-day study
was determined by performing six independent preparation of
the standard preparation of drug substance (150 mg/mL). The
percent RSD of main peak area was found to be less than
0.5%. Inter-day precision was determined by performing ﬁve
different conditions along with the six replicates for each
condition, which is equivalent to n¼30 (5 6). The percent
RSD of the main peak area was found to be less than 0.5%
within each set and less than 3.0% between different sets. The
percent recovery was found to be between 95.0% and 105.0%
and the maximum variation between sets was found to be less
than 5.0%.
The intra-day (repeatability) (n¼6) was assessed with six
independent sample preparations for 150 mg/mL of PTH.
Inter-day (intermediate precision) was determined by perform-
ing ﬁve different types of condition along with the six replicates,which is equivalent to n¼30 (5 6) and percent RSD for the
main peak area within set and between different sets was found
to be less than 1.0%. The percent recovery of PTH standard
was found to be between 95% and 105% within set and
maximum variation between sets was found to be 5.0%.
3.2.2.5. Robustness. The robustness is a measure of its capa-
city to remain unaffected by small, but deliberate variations in
method parameters and provides an indication of its robustness
during normal usage. Robustness was tested using three
variables, age effect of mobile phase and test samples, column
temperature and mobile phase composition.
3.2.2.6. Age effect of mobile phase and test samples held for
seven days. Freshly prepared samples for system suitability
(150 mg/mL of PTH) and those prepared seven days ago were
Figure 5 UPLC chromatograms of meta cresol and PTH drug product (with meta-cresol). PTH drug product—containing 0.250 mg/mL
of PTH and 3 mg/mL ‘meta-cresol’.
Figure 6 UPLC chromatogram of PTH oxidized form. Oxidized form of PTH was prepared by adding 4.0 mL of diluted 0.25% H2O2 to
62.6 mL of PTH drug substance (0.4 mg/mL), mixed well, incubated for 40 min at room temperature and then quenched with 37.4 mL of
50 mg/mL methionine.
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mobile phase. There was not much variation in the results,
with percent variation from initial day to 7 day being about
5% and percent RSD being less than 1.0%. There was no
difference in the retention time and percent recovery was
found to be in between 95% and 105%, indicating that age of
the mobile phase was not a critical parameter.
3.2.2.7. Column temperature effect. Experiments were con-
ducted using system suitability samples with column tempera-
ture variation of þ5 1C from the set temperature (60 1C). The
percent RSD was found to be less than 2%, with variation of
þ0.1 min in the retention time. The percent recovery wasfound to be within acceptable limits (95–105%) suggesting
that the variation in the results was within acceptable limits
for all the parameters under study and indicating that column
temperature was not a critical parameter.
3.2.2.8. Mobile phase composition. Experiments were con-
ducted using system suitability samples with mobile phase
composition variation of 720% from the set percentage of
TFA (0.1%). Results for triplicate injections (% variation)
between initial condition and altered condition for PTH
sample were found to vary less than 2.0% and there was no
variation observed in the retention time, suggesting that the
mobile phase composition was not a critical parameter.
Figure 7 Linearity curve (UPLC) for PTH. PTH drug substance
(400 mg/mL) was diluted with mobile phase ‘A’ for preparation of
different concentrations ranging from 50 to 300 mg/mL, which
were injected separately.
S.S. Rane et al.1423.3. Comparative study of HPLC and UPLC performance
The performance parameters of both systems are shown in
Table 1. The runtime of UPLC was reduced by 7-fold to that
of HPLC. The retention behaviors of meta-cresol, PTH, and
oxidized impurities were similar in HPLC and UPLC columns.
As expected, the UPLC method showed higher efﬁciency of
analysis than HPLC method.4. Conclusion
Both RP-HPLC and RP-UPLC methods were demonstrated
to be validated for quantifying PTH, respectively, in presence
of other excipients and oxidized impurities of PTH. The
HPLC and UPLC methods were validated showing satisfac-
tory data for all the parameters tested. The UPLC method was
found to be capable of giving faster analysis with good
resolution, accuracy and precision than that achieved with
conventional HPLC method. Both the chromatographic
methods described here were found to be reliable for quantify-
ing PTH. Since these methods are rapid and simple, they may
be successfully applied to quality control analyses of ﬁnished
(formulated) product in presence of meta-cresol.
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